Peer-reviewed veterinary case report
Dogs with natural cancer treated safely with CIGB-552 peptide
By Vallespi, Maribel G et al.·Published in Research in veterinary science·2017·Pharmaceutical Department·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The first report of cases of pet dogs with naturally occurring cancer treated with the antitumor peptide CIGB-552.
- Species:
- dog
Plain-English summary
A small group of nine dogs with naturally occurring cancer received a new treatment called CIGB-552, which is a synthetic peptide designed to reduce tumor size. The dogs were given different doses of the peptide, and none experienced serious side effects. The treatment showed promise by decreasing the size of the tumors in these dogs. This suggests that CIGB-552 could be a potential option for treating cancer in pets, and possibly even in humans in the future.
People also search for: dog cancer treatment options · CIGB-552 for dogs · reducing tumor size in dogs · synthetic peptide cancer therapy for pets
Abstract
The absence of an effective therapy against human solid tumors has fostered the development of promising antineoplastic therapeutic candidates, as the CIGB-552 peptide. This synthetic peptide has shown to be effective in reducing tumor size and increasing the lifespan in tumor-bearing mice. Therefore, this work was aimed to explore the safety profile and preliminary assessment of antitumor activity of the CIGB-552 peptide therapeutic candidate in a small population of dogs (n=9) having malignant spontaneously-arising solid tumors. The peptide was administered by subcutaneous (s.c.) route, at three dosage levels (0.075, 0.15 and 0.3mg/kg). The results showed no dose-limiting toxicities in any dogs. The antitumor activity observed in dogs receiving CIGB-552 was associated with the reduction in the tumor volume. Given the antitumor effects of CIGB-552 as mediated by COMMD1 protein, which function is highly conserved among eukaryotic organisms, and the similarities of canine and human types of cancer with respect to tumor biology, it is likely that CIGB-552 could demonstrate comparable anti-cancer activity in human patients. Synthetic peptide, COMMD1, Tumor, Dog, CIGB-552.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28987957/